Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| natural killer cell | 13 studies | 23% ± 7% | |
| gamma-delta T cell | 10 studies | 33% ± 15% | |
| CD16-negative, CD56-bright natural killer cell, human | 8 studies | 25% ± 3% | |
| oligodendrocyte precursor cell | 6 studies | 25% ± 11% | |
| CD16-positive, CD56-dim natural killer cell, human | 4 studies | 27% ± 7% | |
| mature NK T cell | 3 studies | 42% ± 17% |
Insufficient scRNA-seq data for expression of KLRC2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| brain | 95% | 102.56 | 2514 / 2642 | 78% | 26.43 | 549 / 705 |
| lung | 88% | 43.18 | 506 / 578 | 13% | 0.46 | 155 / 1155 |
| spleen | 99% | 106.63 | 239 / 241 | 0% | 0 | 0 / 0 |
| stomach | 66% | 21.64 | 236 / 359 | 15% | 0.37 | 42 / 286 |
| intestine | 51% | 22.61 | 493 / 966 | 18% | 0.51 | 97 / 527 |
| prostate | 56% | 13.23 | 138 / 245 | 6% | 0.25 | 31 / 502 |
| peripheral blood | 59% | 41.73 | 550 / 929 | 0% | 0 | 0 / 0 |
| thymus | 54% | 13.02 | 351 / 653 | 5% | 0.14 | 30 / 605 |
| bladder | 43% | 16.05 | 9 / 21 | 14% | 0.37 | 72 / 504 |
| uterus | 31% | 5.14 | 52 / 170 | 23% | 0.73 | 104 / 459 |
| breast | 36% | 9.35 | 164 / 459 | 8% | 0.21 | 89 / 1118 |
| esophagus | 23% | 4.01 | 328 / 1445 | 16% | 0.38 | 29 / 183 |
| adipose | 38% | 9.16 | 462 / 1204 | 0% | 0 | 0 / 0 |
| ovary | 29% | 5.91 | 53 / 180 | 1% | 0.02 | 6 / 430 |
| liver | 26% | 4.89 | 58 / 226 | 2% | 0.04 | 7 / 406 |
| skin | 8% | 1.33 | 142 / 1809 | 16% | 0.64 | 75 / 472 |
| pancreas | 13% | 2.02 | 42 / 328 | 10% | 0.60 | 17 / 178 |
| tonsil | 0% | 0 | 0 / 0 | 22% | 0.54 | 10 / 45 |
| blood vessel | 15% | 2.65 | 195 / 1335 | 0% | 0 | 0 / 0 |
| kidney | 10% | 1.74 | 9 / 89 | 2% | 0.04 | 18 / 901 |
| lymph node | 0% | 0 | 0 / 0 | 10% | 0.15 | 3 / 29 |
| adrenal gland | 5% | 0.94 | 13 / 258 | 2% | 0.10 | 4 / 230 |
| heart | 6% | 0.84 | 52 / 861 | 0% | 0 | 0 / 0 |
| muscle | 1% | 0.20 | 12 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0007165 | Biological process | signal transduction |
| GO_0002250 | Biological process | adaptive immune response |
| GO_0002228 | Biological process | natural killer cell mediated immunity |
| GO_0006968 | Biological process | cellular defense response |
| GO_0045954 | Biological process | positive regulation of natural killer cell mediated cytotoxicity |
| GO_0043323 | Biological process | positive regulation of natural killer cell degranulation |
| GO_0032814 | Biological process | regulation of natural killer cell activation |
| GO_0002223 | Biological process | stimulatory C-type lectin receptor signaling pathway |
| GO_0009897 | Cellular component | external side of plasma membrane |
| GO_0043235 | Cellular component | receptor complex |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0004888 | Molecular function | transmembrane signaling receptor activity |
| GO_1990405 | Molecular function | protein antigen binding |
| GO_0062081 | Molecular function | activating MHC class Ib receptor activity |
| GO_0030246 | Molecular function | carbohydrate binding |
| GO_0005515 | Molecular function | protein binding |
| GO_0023024 | Molecular function | MHC class I protein complex binding |
| Gene name | KLRC2 |
| Protein name | KLRC2 protein Killer cell lectin like receptor C2 NKG2-C type II integral membrane protein (CD159 antigen-like family member C) (NK cell receptor C) (NKG2-C-activating NK receptor) (CD antigen CD159c) |
| Synonyms | NKG2C |
| Description | FUNCTION: Immune activating receptor involved in self-nonself discrimination. In complex with KLRD1 on cytotoxic lymphocyte subsets, recognizes non-classical major histocompatibility (MHC) class Ib HLA-E loaded with signal sequence-derived peptides from non-classical MHC class Ib HLA-G molecules, likely playing a role in the generation and effector functions of adaptive natural killer (NK) cells and in maternal-fetal tolerance during pregnancy . Regulates the effector functions of terminally differentiated cytotoxic lymphocyte subsets, and in particular may play a role in adaptive NK cell response to viral infection . Upon HLA-E-peptide binding, transmits intracellular signals via the adapter protein TYROBP/DAP12, triggering the phosphorylation of proximal signaling molecules and cell activation . . |
| Accessions | F5H518 P26717 H0YFK4 Q3KQS7 ENST00000535069.5 ENST00000381902.7 ENST00000536833.6 ENST00000537017.1 J3KPJ4 H0YGY2 ENST00000381901.5 |
